X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The combined company will accelerate development of Conduit’s autoimmune disease and idiopathic male infertility pipeline, including AZD5904, a potent orally bioavailable MPO inhibitor.
Lead Product(s): AZD5904
Therapeutic Area: Endocrinology Product Name: AZD5904
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Murphy Canyon Acquisition
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 22, 2023
Details:
AZD5904 is a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Lead Product(s): AZD5904
Therapeutic Area: Endocrinology Product Name: AZD5904
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Murphy Canyon Acquisition Corp.
Deal Size: $27.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
